Concepedia

Anjan Thakurta

AT

57

Publications

4.6K

Citations

30

H-Index

2002

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Harvard University

Dana-Farber Cancer Institute

Inserm

University of Oxford

Anjan Thakurta is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and pathology.

ORCID

Top concepts

Publications per year

2002–2024

57

Publications

57

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> <sup>CRBN</sup> </scp>

Anita K. Gandhi, Jian Kang, Courtney G. Havens et al. · British Journal of Haematology · 2013 · 611 citations · Full text

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell et al. · Blood · 2018 · 478 citations · Full text

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell et al. · Leukemia · 2018 · 440 citations · Full text

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Michael Amatangelo, Lynn Quek, Alan H. Shih et al. · Blood · 2017 · 346 citations · Full text

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Chad C. Bjorklund, Ling Lu, Jian Kang et al. · Blood Cancer Journal · 2015 · 211 citations · Full text

Rows per page

1–5 of 57